Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer
Introduction. Recently, the he-4 protein has received great attention due to its diagnostic and prognostic abilities in epithelial ovarian cancer. In addition to its diagnostic value, this protein is involved in the pathogenesis of ovarian cancer. Another significant pathogenetic factor is the vascu...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2022-01-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1988 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849253162868801536 |
|---|---|
| author | E. M. Frantsiyants T. I. Moiseenko D. Yu. Yakubova N. D. Cheryarina A. P. Menshenina E. V. Verenikina M. L. Adamyan |
| author_facet | E. M. Frantsiyants T. I. Moiseenko D. Yu. Yakubova N. D. Cheryarina A. P. Menshenina E. V. Verenikina M. L. Adamyan |
| author_sort | E. M. Frantsiyants |
| collection | DOAJ |
| description | Introduction. Recently, the he-4 protein has received great attention due to its diagnostic and prognostic abilities in epithelial ovarian cancer. In addition to its diagnostic value, this protein is involved in the pathogenesis of ovarian cancer. Another significant pathogenetic factor is the vascular endothelial growth factor (vegf) which plays a key role in neoangiogenesis. The purpose of the study focused on the analysis of he-4 and vegf-a levels in tissues of ovarian cancer, in healthy contralateral ovaries and in common metastatic tumors in the omentum and peritoneum to determine the place and role of these tumor markers at the stages of carcinogenesis. Material and methods. The study was performed using the abovementioned tissues of 93 patients with t2-3nхm0-1 ovarian cancer. 51 patients underwent surgery followed by chemotherapy. 42 patients received initial neoadjuvant chemotherapy followed by surgery and adjuvant cytostatic therapy. Tissue samples from 17 patients with benign diseases were used as the control for determining the reference values for he-4 and vegf-a. A comparison was made between groups of patients with and without neoadjuvant therapy, as well as in groups of patients depending on the effectiveness of cytostatic treatment. Results. The levels of he-4 in primary and metastatic tissues affected and not affected by cancer were initially elevated in patients with ovarian cancer. The chemotherapy effectiveness directly correlated with the level of he-4 reduction, which did not change or increased in tumors resistant to medical treatment. The level of vegf-a significantly differed in cancer and non-cancer tissues, which indicated its significant pathogenetic effect not “before”, but at the stages of morphological malignization. The dynamics of vegf-a decrease in this study did not depend on the chemotherapy effect. Conclusion. The he-4 marker is a pathognomonic factor in the development of ovarian cancer, preceding morphological signs of malignancy and reflecting the effectiveness of chemotherapy, while vegf-a is most likely a consequence of the cancer development. |
| format | Article |
| id | doaj-art-85473a2a77fb446c9b7dcd7073555bf6 |
| institution | Kabale University |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2022-01-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-85473a2a77fb446c9b7dcd7073555bf62025-08-20T03:56:24ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682022-01-01206697710.21294/1814-4861-2021-20-6-69-77925Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancerE. M. Frantsiyants0T. I. Moiseenko1D. Yu. Yakubova2N. D. Cheryarina3A. P. Menshenina4E. V. Verenikina5M. L. Adamyan6National Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyIntroduction. Recently, the he-4 protein has received great attention due to its diagnostic and prognostic abilities in epithelial ovarian cancer. In addition to its diagnostic value, this protein is involved in the pathogenesis of ovarian cancer. Another significant pathogenetic factor is the vascular endothelial growth factor (vegf) which plays a key role in neoangiogenesis. The purpose of the study focused on the analysis of he-4 and vegf-a levels in tissues of ovarian cancer, in healthy contralateral ovaries and in common metastatic tumors in the omentum and peritoneum to determine the place and role of these tumor markers at the stages of carcinogenesis. Material and methods. The study was performed using the abovementioned tissues of 93 patients with t2-3nхm0-1 ovarian cancer. 51 patients underwent surgery followed by chemotherapy. 42 patients received initial neoadjuvant chemotherapy followed by surgery and adjuvant cytostatic therapy. Tissue samples from 17 patients with benign diseases were used as the control for determining the reference values for he-4 and vegf-a. A comparison was made between groups of patients with and without neoadjuvant therapy, as well as in groups of patients depending on the effectiveness of cytostatic treatment. Results. The levels of he-4 in primary and metastatic tissues affected and not affected by cancer were initially elevated in patients with ovarian cancer. The chemotherapy effectiveness directly correlated with the level of he-4 reduction, which did not change or increased in tumors resistant to medical treatment. The level of vegf-a significantly differed in cancer and non-cancer tissues, which indicated its significant pathogenetic effect not “before”, but at the stages of morphological malignization. The dynamics of vegf-a decrease in this study did not depend on the chemotherapy effect. Conclusion. The he-4 marker is a pathognomonic factor in the development of ovarian cancer, preceding morphological signs of malignancy and reflecting the effectiveness of chemotherapy, while vegf-a is most likely a consequence of the cancer development.https://www.siboncoj.ru/jour/article/view/1988ovarian cancerpolychemotherapyhe-4 proteinvegf-acytostatic therapyplatinum resistance of ovarian cancer |
| spellingShingle | E. M. Frantsiyants T. I. Moiseenko D. Yu. Yakubova N. D. Cheryarina A. P. Menshenina E. V. Verenikina M. L. Adamyan Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer Сибирский онкологический журнал ovarian cancer polychemotherapy he-4 protein vegf-a cytostatic therapy platinum resistance of ovarian cancer |
| title | Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer |
| title_full | Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer |
| title_fullStr | Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer |
| title_full_unstemmed | Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer |
| title_short | Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer |
| title_sort | influence of initial platinum based chemotherapy on levels of he 4 protein and vegf a in primary tumors and metastases from ovarian cancer |
| topic | ovarian cancer polychemotherapy he-4 protein vegf-a cytostatic therapy platinum resistance of ovarian cancer |
| url | https://www.siboncoj.ru/jour/article/view/1988 |
| work_keys_str_mv | AT emfrantsiyants influenceofinitialplatinumbasedchemotherapyonlevelsofhe4proteinandvegfainprimarytumorsandmetastasesfromovariancancer AT timoiseenko influenceofinitialplatinumbasedchemotherapyonlevelsofhe4proteinandvegfainprimarytumorsandmetastasesfromovariancancer AT dyuyakubova influenceofinitialplatinumbasedchemotherapyonlevelsofhe4proteinandvegfainprimarytumorsandmetastasesfromovariancancer AT ndcheryarina influenceofinitialplatinumbasedchemotherapyonlevelsofhe4proteinandvegfainprimarytumorsandmetastasesfromovariancancer AT apmenshenina influenceofinitialplatinumbasedchemotherapyonlevelsofhe4proteinandvegfainprimarytumorsandmetastasesfromovariancancer AT evverenikina influenceofinitialplatinumbasedchemotherapyonlevelsofhe4proteinandvegfainprimarytumorsandmetastasesfromovariancancer AT mladamyan influenceofinitialplatinumbasedchemotherapyonlevelsofhe4proteinandvegfainprimarytumorsandmetastasesfromovariancancer |